|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
Statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar
|
|
2
|
Pectasides D, Kamposioras K, Papaxoinis G
and Pectasides E: Chemotherapy for recurrent cervical cancer.
Cancer Treat Rev. 34:603–613. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Li S, Hu T, Lv W, et al: Changes in
prevalence and clinical characteristics of cervical cancer in the
People’s Republic of China: a study of 10,012 cases from a
nationwide working group. Oncologist. 18:1101–1107. 2013.
|
|
4
|
Yee GP, de Souza P and Khachigian LM:
Current and potential treatments for cervical cancer. Curr Cancer
Drug Targets. 13:205–220. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ahmad A, Wang Z, Kong D, et al: FoxM1
down-regulation leads to inhibition of proliferation, migration and
invasion of breast cancer cells through the modulation of
extra-cellular matrix degrading factors. Breast Cancer Res Treat.
122:337–346. 2010. View Article : Google Scholar
|
|
6
|
Kim IM, Ackerson T, Ramakrishna S, et al:
The Forkhead Box m1 transcription factor stimulates the
proliferation of tumor cells during development of lung cancer.
Cancer Res. 66:2153–2161. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu M, Dai B, Kang SH, et al: FoxM1B is
overexpressed in human glioblastomas and critically regulates the
tumorigenicity of glioma cells. Cancer Res. 66:3593–3602. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang Z, Banerjee S, Kong D, Li Y and
Sarkar FH: Downregulation of Forkhead Box M1 transcription factor
leads to the inhibition of invasion and angiogenesis of pancreatic
cancer cells. Cancer Res. 67:8293–8300. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Feng Y, Wang L, Zeng J, et al: FoxM1 is
overexpressed in Helicobacter pylori-induced gastric
carcinogenesis and is negatively regulated by miR-370. Mol Cancer
Res. 11:834–844. 2013.
|
|
10
|
Kalinichenko VV, Major ML, Wang X, et al:
Foxm1b transcription factor is essential for development of
hepatocellular carcinomas and is negatively regulated by the
p19ARF tumor suppressor. Genes Dev. 18:830–850. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chan DW, Yu SY, Chiu PM, et al:
Over-expression of FOXM1 transcription factor is associated with
cervical cancer progression and pathogenesis. J Pathol.
215:245–252. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Guan P, Chen H, Li HJ, Duan J and Chen JY:
Expression and significance of FOXM1 in human cervical cancer: a
tissue micro-array study. Clin Invest Med. 34:E1–E7.
2011.PubMed/NCBI
|
|
13
|
Khongkow P, Karunarathna U, Khongkow M, et
al: FOXM1 targets NBS1 to regulate DNA damage-induced senescence
and epirubicin resistance. Oncogene. Oct 21–2013.(Epub ahead of
print). View Article : Google Scholar
|
|
14
|
Raychaudhuri P and Park HJ: FoxM1: a
master regulator of tumor metastasis. Cancer Res. 71:4329–4333.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li Y, Ligr M, McCarron JP, et al:
Natura-alpha targets forkhead box m1 and inhibits
androgen-dependent and -independent prostate cancer growth and
invasion. Clin Cancer Res. 17:4414–4424. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sun H, Teng M, Liu J, et al: FOXM1
expression predicts the prognosis in hepatocellular carcinoma
patients after orthotopic liver transplantation combined with the
Milan criteria. Cancer Lett. 306:214–222. 2011. View Article : Google Scholar
|
|
17
|
Li Q, Zhang N, Jia Z, et al: Critical role
and regulation of transcription factor FoxM1 in human gastric
cancer angiogenesis and progression. Cancer Res. 69:3501–3509.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wierstra I and Alves J: FOXM1, a typical
proliferation-associated transcription factor. Biol Chem.
388:1257–1274. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang IC, Chen YJ, Hughes D, et al:
Forkhead box M1 regulates the transcriptional network of genes
essential for mitotic progression and genes encoding the SCF
(Skp2-Cks1) ubiquitin ligase. Mol Cell Biol. 25:10875–10894. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Laoukili J, Kooistra MR, Bras A, et al:
FoxM1 is required for execution of the mitotic programme and
chromosome stability. Nat Cell Biol. 7:126–136. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cao Y, EG, Wang E, et al: VEGF exerts an
angiogenesis-independent function in cancer cells to promote their
malignant progression. Cancer Res. 72:3912–3918. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Naito S, von Eschenbach AC, Giavazzi R and
Fidler IJ: Growth and metastasis of tumor cells isolated from a
human renal cell carcinoma implanted into different organs of nude
mice. Cancer Res. 46:4109–4115. 1986.PubMed/NCBI
|
|
23
|
Kim YH, Kim MA, Park IA, et al: VEGF
polymorphisms in early cervical cancer susceptibility,
angiogenesis, and survival. Gynecol Oncol. 119:232–236. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Green DR and Evan GI: A matter of life and
death. Cancer Cell. 1:19–30. 2002. View Article : Google Scholar
|
|
25
|
Katoh M and Katoh M: Human FOX gene family
(Review). Int J Oncol. 25:1495–1500. 2004.PubMed/NCBI
|
|
26
|
Ahmed M, Uddin S, Hussain AR, et al: FoxM1
and its association with matrix metalloproteinases (MMP) signaling
pathway in papillary thyroid carcinoma. J Clin Endocrinol Metab.
97:E1–E13. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Uddin S, Ahmed M, Hussain A, et al:
Genome-wide expression analysis of Middle Eastern colorectal cancer
reveals FOXM1 as a novel target for cancer therapy. Am J Pathol.
178:537–547. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen X, Muller GA, Quaas M, et al: The
forkhead transcription factor FOXM1 controls cell cycle-dependent
gene expression through an atypical chromatin binding mechanism.
Mol Cell Biol. 33:227–236. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Halasi M and Gartel AL: Suppression of
FOXM1 sensitizes human cancer cells to cell death induced by
DNA-damage. PLoS One. 7:e317612012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kallakury BV, Karikehalli S, Haholu A,
Sheehan CE, Azumi N and Ross JS: Increased expression of matrix
metalloproteinases 2 and 9 and tissue inhibitors of
metalloproteinases 1 and 2 correlate with poor prognostic variables
in renal cell carcinoma. Clin Cancer Res. 7:3113–3119.
2001.PubMed/NCBI
|
|
31
|
Maatta M, Soini Y, Liakka A and
Autio-Harmainen H: Differential expression of matrix
metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in
hepatocellular and pancreatic adenocarcinoma: implications for
tumor progression and clinical prognosis. Clin Cancer Res.
6:2726–2734. 2000.
|
|
32
|
Klein G, Vellenga E, Fraaije MW, Kamps WA
and de Bont ES: The possible role of matrix metalloproteinase
(MMP)-2 and MMP-9 in cancer, e.g acute leukemia. Crit Rev Oncol
Hematol. 50:87–100. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Passlick B, Sienel W, Seen-Hibler R, et
al: Overexpression of matrix metalloproteinase 2 predicts
unfavorable outcome in early-stage non-small cell lung cancer. Clin
Cancer Res. 6:3944–3948. 2000.PubMed/NCBI
|
|
34
|
Xue YJ, Xiao RH, Long DZ, et al:
Overexpression of FoxM1 is associated with tumor progression in
patients with clear cell renal cell carcinoma. J Transl Med.
10:2002012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Dai B, Kang SH, Gong W, et al: Aberrant
FoxM1B expression increases matrix metalloproteinase-2
transcription and enhances the invasion of glioma cells. Oncogene.
26:6212–6219. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gorantla B, Asuthkar S, Rao JS, Patel J
and Gondi CS: Suppression of the uPAR-uPA system retards
angiogenesis, invasion, and in vivo tumor development in pancreatic
cancer cells. Mol Cancer Res. 9:377–389. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Raghu H, Nalla AK, Gondi CS, Gujrati M,
Dinh DH and Rao JS: uPA and uPAR shRNA inhibit angiogenesis via
enhanced secretion of SVEGFR1 independent of GM-CSF but dependent
on TIMP-1 in endothelial and glioblastoma cells. Mol Oncol.
6:33–47. 2012. View Article : Google Scholar
|
|
38
|
Pulukuri SM, Gondi CS, Lakka SS, et al:
RNA interference-directed knockdown of urokinase plasminogen
activator and urokinase plasminogen activator receptor inhibits
prostate cancer cell invasion, survival, and tumorigenicity in
vivo. J Biol Chem. 280:36529–36540. 2005. View Article : Google Scholar
|
|
39
|
Zhao R, Liu XQ, Wu XP, et al: Vascular
endothelial growth factor (VEGF) enhances gastric carcinoma
invasiveness via integrin alpha(v)beta6. Cancer Lett. 287:150–156.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lee J, Lee J, Yu H, Choi K and Choi C:
Differential dependency of human cancer cells on vascular
endothelial growth factor-mediated autocrine growth and survival.
Cancer Lett. 309:145–150. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Risau W: Mechanisms of angiogenesis.
Nature. 386:671–674. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Folkman J: Angiogenesis. Annu Rev Med.
57:1–18. 2006. View Article : Google Scholar
|
|
43
|
Zhang Y, Zhang N, Dai B, et al: FoxM1B
transcriptionally regulates vascular endothelial growth factor
expression and promotes the angiogenesis and growth of glioma
cells. Cancer Res. 68:8733–8742. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Cai Y, Balli D, Ustiyan V, et al: Foxm1
expression in prostate epithelial cells is essential for prostate
carcinogenesis. J Biol Chem. 288:22527–22541. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
No JH, Jo H, Kim SH, et al: Expression of
MMP-2, MMP-9, and urokinase-type plasminogen activator in cervical
intraepithelial neoplasia. Ann NY Acad Sci. 1171:100–104. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Fang J, Shing Y, Wiederschain D, et al:
Matrix metalloproteinase-2 is required for the switch to the
angiogenic phenotype in a tumor model. Proc Natl Acad Sci USA.
97:3884–3889. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Silletti S, Kessler T, Goldberg J, Boger
DL and Cheresh DA: Disruption of matrix metalloproteinase 2 binding
to integrin alpha vbeta 3 by an organic molecule inhibits
angiogenesis and tumor growth in vivo. Proc Natl Acad Sci USA.
98:119–124. 2001.PubMed/NCBI
|
|
48
|
Chetty C, Bhoopathi P, Joseph P,
Chittivelu S, Rao JS and Lakka S: Adenovirus-mediated small
interfering RNA against matrix metalloproteinase-2 suppresses tumor
growth and lung metastasis in mice. Mol Cancer Ther. 5:2289–2299.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Chetty C, Lakka SS, Bhoopathi P and Rao
JS: MMP-2 alters VEGF expression via alphaVbeta3 integrin-mediated
PI3K/AKT signaling in A549 lung cancer cells. Int J Cancer.
127:1081–1095. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
He SY, Shen HW, Xu L, et al: FOXM1
promotes tumor cell invasion and correlates with poor prognosis in
early-stage cervical cancer. Gynecol Oncol. 127:601–610. 2012.
View Article : Google Scholar : PubMed/NCBI
|
